AW
RCUS icon

Ankerstar Wealth’s Arcus Biosciences RCUS Stock Holding History

Ankerstar Wealth’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247 Hold
8
– – ﹤0.01% 850
2026
Q1 		$173 Sell
8
-3
-27% -$65 ﹤0.01% 868
2025
Q4 		$262 Buy
+11
New +$224 ﹤0.01% 824

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ankerstar Wealth's RCUS Position: Q2 2026 in Review

Ankerstar Wealth held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 8 shares worth $247. The position accounts for ﹤0.01% of the portfolio, ranked #850.

Ankerstar Wealth first reported a position in RCUS in Q4 2025 and has held it in 3 quarters since. The position peaked at $262 in Q4 2025. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Ankerstar Wealth held 8 shares of Arcus Biosciences worth $247 as of Q2 2026.
  • Ankerstar Wealth left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Ankerstar Wealth's portfolio in Q2 2026, its #850 holding.
  • Ankerstar Wealth first reported a position in Arcus Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Ankerstar Wealth's Arcus Biosciences position peaked at $262 in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Ankerstar Wealth's 13F filing for Q2 2026, filed 13 Aug 2026.